[Inflammatory bowel disease and colorectal cancer].
The colorectal cancer is one of the most serious complication of inflammatory bowel disease. Longer duration of the disease, extensive colitis, primary sclerosing cholangitis, family history of colorectal cancer are the main risk factors. The relative risk of colorectal cancer in ulcerative colitis is increased, however, there're marked geographically differences. Relative risk of colorectal cancer is 2.5 and small bowel cancer risk is 31.2 in Crohn's disease. There aren't prospective, randomized, controlled trials that definitively prove the benefit of surveillance of colorectal cancer in IBD. Colonoscopy improve the 5-year survival rate, however, there is no evidence for the reduction of mortality. Meta-analysis showed efficacy of mesalamine in the reduction of risk of colorectal cancer, but prospective trials have been missed. Chemoprotective role of other immunomodulators has not been proven yet.
Hagymási
Krisztina
K
Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Budapest. hagymasikriszti@freemail.hu
Tulassay
Zsolt
Z
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D015209:Cholangitis, Sclerosing / Q000150:complications; D003093:Colitis, Ulcerative / Q000150:complications; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control; D003424:Crohn Disease / Q000150:complications; D006801:Humans; D015994:Incidence; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D007414:Intestinal Neoplasms / Q000209:etiology / Q000503:physiopathology; D007421:Intestine, Small / Q000503:physiopathology; D008403:Mass Screening; D019804:Mesalamine / Q000627:therapeutic use; D011159:Population Surveillance; D018570:Risk Assessment; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine